
BiotechTV - News
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
19 min•14 april 2025
Om avsnittet
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.
Fler avsnitt
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.